These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 2968349)

  • 21. The effect of aldose reductase inhibitors on glomerular prostaglandin production and urinary albumin excretion in experimental diabetes mellitus.
    Chang WP; Dimitriadis E; Allen T; Dunlop ME; Cooper M; Larkins RG
    Diabetologia; 1991 Apr; 34(4):225-31. PubMed ID: 1906023
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Deficiency of ascorbic acid in experimental diabetes. Relationship with collagen and polyol pathway abnormalities.
    McLennan S; Yue DK; Fisher E; Capogreco C; Heffernan S; Ross GR; Turtle JR
    Diabetes; 1988 Mar; 37(3):359-61. PubMed ID: 2836250
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aldose reductase inhibition and glomerular abnormalities in diabetic rats.
    Daniels BS; Hostetter TH
    Diabetes; 1989 Aug; 38(8):981-6. PubMed ID: 2502460
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Glomerular polyol accumulation in diabetes and its prevention by oral sorbinil.
    Beyer-Mears A; Ku L; Cohen MP
    Diabetes; 1984 Jun; 33(6):604-7. PubMed ID: 6427041
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nonosmotic diabetic cataracts.
    Malone JI; Lowitt S; Cook WR
    Pediatr Res; 1990 Mar; 27(3):293-6. PubMed ID: 2138728
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ascorbic acid metabolism and polyol pathway in diabetes.
    Yue DK; McLennan S; Fisher E; Heffernan S; Capogreco C; Ross GR; Turtle JR
    Diabetes; 1989 Feb; 38(2):257-61. PubMed ID: 2492477
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aldose reductase, diabetes, and thickening of the retinal inner limiting membrane.
    Nagata M; Robison WG
    Invest Ophthalmol Vis Sci; 1987 Nov; 28(11):1867-9. PubMed ID: 3117719
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glucose-induced microvascular functional changes in nondiabetic rats are stereospecific and are prevented by an aldose reductase inhibitor.
    Williamson JR; Ostrow E; Eades D; Chang K; Allison W; Kilo C; Sherman WR
    J Clin Invest; 1990 Apr; 85(4):1167-72. PubMed ID: 2108189
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Administration of ascorbic acid and an aldose reductase inhibitor (tolrestat) in diabetes: effect on urinary albumin excretion.
    McAuliffe AV; Brooks BA; Fisher EJ; Molyneaux LM; Yue DK
    Nephron; 1998 Nov; 80(3):277-84. PubMed ID: 9807036
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nitric oxide prevents aldose reductase activation and sorbitol accumulation during diabetes.
    Chandra D; Jackson EB; Ramana KV; Kelley R; Srivastava SK; Bhatnagar A
    Diabetes; 2002 Oct; 51(10):3095-101. PubMed ID: 12351453
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevention of defects of axonal transport and nerve conduction velocity by oral administration of myo-inositol or an aldose reductase inhibitor in streptozotocin-diabetic rats.
    Mayer JH; Tomlinson DR
    Diabetologia; 1983 Nov; 25(5):433-8. PubMed ID: 6197336
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diabetes-related histopathologies of the rat retina prevented with an aldose reductase inhibitor.
    Robison WG; Tillis TN; Laver N; Kinoshita JH
    Exp Eye Res; 1990 Apr; 50(4):355-66. PubMed ID: 2110907
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effects of an aldose reductase inhibitor upon the sorbitol pathway, fructose-1-phosphate and lactate in the retina and nerve of streptozotocin-diabetic rats.
    Poulsom R; Mirrlees DJ; Earl DC; Heath H
    Exp Eye Res; 1983 May; 36(5):751-60. PubMed ID: 6406254
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of hyperglycemia and the aldose reductase inhibitor tolrestat on sural nerve biochemistry and morphometry in advanced diabetic peripheral polyneuropathy. The Tolrestat Study Group.
    Sima AA; Greene DA; Brown MB; Hohman TC; Hicks D; Graepel GJ; Bochenek WJ; Beg M; Gonen B
    J Diabetes Complications; 1993; 7(3):157-69. PubMed ID: 8343610
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aldose reductase and retinal capillary basement membrane thickening.
    Robison WG; Nagata M; Kinoshita JH
    Exp Eye Res; 1988 Mar; 46(3):343-8. PubMed ID: 3127228
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of aldose reductase inhibitor ONO 2235 on reduced sympathetic nervous system activity and peripheral nerve disorders in STZ-induced diabetic rats.
    Yoshida T; Nishioka H; Yoshioka K; Nakano K; Kondo M; Terashima H
    Diabetes; 1987 Jan; 36(1):6-13. PubMed ID: 3025043
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Myo-inositol and sorbitol metabolism in relation to peripheral nerve function in experimental diabetes in the rat: the effect of aldose reductase inhibition.
    Gillon KR; Hawthorne JN; Tomlinson DR
    Diabetologia; 1983 Oct; 25(4):365-71. PubMed ID: 6416913
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effects of aldose reductase inhibition on nerve sorbitol and myoinositol concentrations in diabetic and galactosemic rats.
    Yue DK; Hanwell MA; Satchell PM; Handelsman DJ; Turtle JR
    Metabolism; 1984 Dec; 33(12):1119-22. PubMed ID: 6438438
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of polyol pathway activity in diabetic and galactosemic rats by the aldose reductase inhibitor CP-45,634.
    Peterson MJ; Sarges R; Aldinger CE; MacDonald DP
    Adv Exp Med Biol; 1979; 119():347-56. PubMed ID: 115231
    [No Abstract]   [Full Text] [Related]  

  • 40. Diminished proteinuria in diabetes mellitus by sorbinil, an aldose reductase inhibitor.
    Beyer-Mears A; Cruz E; Edelist T; Varagiannis E
    Pharmacology; 1986; 32(1):52-60. PubMed ID: 3080763
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.